Clinical Trial Update: Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update indicating efficacy and safety of SANGUINATE in reducing delayed graft function in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Delayed Function of Renal Transplant | Phase 2, Phase 3 | Status: COMPLETED